Heparanase-neutralizing A54 monoclonal antibody
AssigneesTechnion Research & Development Foundation Limited, Hadasit Medical Research Services and Development Ltd.
InventorsIsrael Vlodavsky, Uri Barash
Life of this patent
Estimating the term…
Abstract
The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.
Claims13
An antibody or an antigen-binding fragment, analog or derivative thereof, directed against a heparanase enzyme, wherein the antibody, antigen-binding fragment, analog or derivative thereof comprises six complementarity-determining regions (CDRs), of SEQ ID NO:
- 1 to SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.